宜明昂科-B(01541)提交IMM2510 III期临床试验申请

宜明昂科-B(01541)提交IMM2510用于治疗耐药性非小细胞肺癌的III期临床试验申请，股价上涨6.69%，国元国际研报称其研发管线丰富，有望成为重磅药物。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/economy/92c4b57cc171fa2e98d252f2e284036e"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://community-service.laohu8.com/v1/financial/theme/news\",params:#themeId:\"92c4b57cc171fa2e98d252f2e284036e\",region:\"SGP\",,,undefined,":{"bottom":true,"list":[],"size":0,"extra":{"requestId":"33fbbb6f760f4c558cf7ba63c1d0a46d"}},"@#url:\"https://community-service.laohu8.com/v1/theme/info\",params:#region:\"SGP\",,method:\"POST\",data:#themeId:\"92c4b57cc171fa2e98d252f2e284036e\",,,undefined,":{"themeId":"92c4b57cc171fa2e98d252f2e284036e","name":"宜明昂科-B(01541)提交IMM2510 III期临床试验申请","description":"宜明昂科-B(01541)提交IMM2510用于治疗耐药性非小细胞肺癌的III期临床试验申请，股价上涨6.69%，国元国际研报称其研发管线丰富，有望成为重磅药物。","image":"https://static.tigerbbs.com/75893bea54132997d986d37d06d63387","type":2,"style":4,"follow":false,"createTime":1759477546110,"userCounts":0,"rnLink":"https://laohu8.com/RN?name=RNTheme&page=/theme/special/finance&rndata={\"themeId\":92c4b57cc171fa2e98d252f2e284036e}&rnconfig={\"headerBarHidden\": true}","subscribe":false,"allowFollow":false,"hasReward":false,"rewardScore":0,"rewardValidDate":0,"rewardEnd":false,"symbols":["01541"],"tweetCounts":0,"categoryId":"2929bb7468f5415f853fd96fb35d7c3b","options":[],"votedOptionId":"","totalUserCount":0,"followStatus":false,"themeName":"宜明昂科-B(01541)提交IMM2510 III期临床试验申请","tweetAmount":0,"imageIsDefault":false}}}